BACKGROUND: The majority of patients diagnosed with thrombotic thrombocytopenic purpura have autoantibodies directed towards the spacer domain of ADAMTS13. DESIGN AND METHODS: In this study we explored the epitope specificity and immunoglobulin class and immunoglobulin G subclass distribution of anti-ADAMTS13 antibodies. The epitope specificity of anti-spacer domain antibodies was examined using plasma from 48 patients with acute acquired thrombotic thrombocytopenic purpura by means of immunoprecipitation of ADAMTS13 variants containing single or multiple alanine substitutions. Using similar methods, we also determined the presence of anti-TSP2-8 and CUB1-2 domain antibodies in this cohort of patients. RESULTS: Antibody profiling revealed that anti-ADAMTS13 immunoglobulin G1 and immunoglobulin G4 predominate in plasma of patients with acquired thrombotic thrombocytopenic purpura. Analysis of anti-spacer domain antibodies revealed that Arg568 and Phe592, in addition to residues Arg660, Tyr661, and Tyr665, also contribute to an antigenic surface in the spacer domain. The majority of patients (90%) lost reactivity towards the spacer domain following introduction of multiple alanine substitutions at Arg568, Phe592, Arg660, Tyr661 and Tyr665. Anti-TSP2-8 and anti-CUB1-2 domain-directed antibodies were present in, respectively, 17% and 35% of the patients' samples analyzed. CONCLUSIONS: Immunoglobulin G directed towards a single antigenic surface comprising residues Arg568, Phe592, Arg660, Tyr661 and Tyr665 predominates in the plasma of patients with acquired thrombotic thrombocytopenic purpura.
BACKGROUND: The majority of patients diagnosed with thrombotic thrombocytopenic purpura have autoantibodies directed towards the spacer domain of ADAMTS13. DESIGN AND METHODS: In this study we explored the epitope specificity and immunoglobulin class and immunoglobulin G subclass distribution of anti-ADAMTS13 antibodies. The epitope specificity of anti-spacer domain antibodies was examined using plasma from 48 patients with acute acquired thrombotic thrombocytopenic purpura by means of immunoprecipitation of ADAMTS13 variants containing single or multiple alanine substitutions. Using similar methods, we also determined the presence of anti-TSP2-8 and CUB1-2 domain antibodies in this cohort of patients. RESULTS: Antibody profiling revealed that anti-ADAMTS13 immunoglobulin G1 and immunoglobulin G4 predominate in plasma of patients with acquired thrombotic thrombocytopenic purpura. Analysis of anti-spacer domain antibodies revealed that Arg568 and Phe592, in addition to residues Arg660, Tyr661, and Tyr665, also contribute to an antigenic surface in the spacer domain. The majority of patients (90%) lost reactivity towards the spacer domain following introduction of multiple alanine substitutions at Arg568, Phe592, Arg660, Tyr661 and Tyr665. Anti-TSP2-8 and anti-CUB1-2 domain-directed antibodies were present in, respectively, 17% and 35% of the patients' samples analyzed. CONCLUSIONS: Immunoglobulin G directed towards a single antigenic surface comprising residues Arg568, Phe592, Arg660, Tyr661 and Tyr665 predominates in the plasma of patients with acquired thrombotic thrombocytopenic purpura.
Authors: H B Feys; F Liu; N Dong; I Pareyn; S Vauterin; N Vandeputte; W Noppe; C Ruan; H Deckmyn; K Vanhoorelbeke Journal: J Thromb Haemost Date: 2006-05 Impact factor: 5.824
Authors: Brenda M Luken; Ellen A M Turenhout; Paul H P Kaijen; Mascha J Greuter; Wouter Pos; Jan A van Mourik; Rob Fijnheer; Jan Voorberg Journal: Thromb Haemost Date: 2006-09 Impact factor: 5.249
Authors: W Pos; B M Luken; J A Kremer Hovinga; E A M Turenhout; F Scheiflinger; J-F Dong; R Fijnheer; J Voorberg Journal: J Thromb Haemost Date: 2009-03 Impact factor: 5.824
Authors: Hendrik B Feys; Maria T Canciani; Flora Peyvandi; Hans Deckmyn; Karen Vanhoorelbeke; Pier M Mannucci Journal: Br J Haematol Date: 2007-06-29 Impact factor: 6.998
Authors: Jianhua Sui; William C Hwang; Sandra Perez; Ge Wei; Daniel Aird; Li-mei Chen; Eugenio Santelli; Boguslaw Stec; Greg Cadwell; Maryam Ali; Hongquan Wan; Akikazu Murakami; Anuradha Yammanuru; Thomas Han; Nancy J Cox; Laurie A Bankston; Ruben O Donis; Robert C Liddington; Wayne A Marasco Journal: Nat Struct Mol Biol Date: 2009-02-22 Impact factor: 15.369
Authors: Cui Jian; Juan Xiao; Lingjie Gong; Christopher G Skipwith; Sheng-Yu Jin; Hau C Kwaan; X Long Zheng Journal: Blood Date: 2012-01-30 Impact factor: 22.113
Authors: Silvia Ferrari; Kristina Palavra; Bernadette Gruber; Johanna A Kremer Hovinga; Paul Knöbl; Claudine Caron; Caroline Cromwell; Louis Aledort; Barbara Plaimauer; Peter L Turecek; Hanspeter Rottensteiner; Friedrich Scheiflinger Journal: Haematologica Date: 2013-11-15 Impact factor: 9.941
Authors: Rana Grillberger; Veronica C Casina; Peter L Turecek; X Long Zheng; Hanspeter Rottensteiner; Friedrich Scheiflinger Journal: Haematologica Date: 2014-02-14 Impact factor: 9.941
Authors: Eric M Ostertag; Stephen Kacir; Michelle Thiboutot; Gayathri Gulendran; X Long Zheng; Douglas B Cines; Don L Siegel Journal: Transfusion Date: 2016-04-04 Impact factor: 3.157
Authors: Fabian C Verbij; Nicoletta Sorvillo; Paul H P Kaijen; Johana Hrdinova; Ivan Peyron; Rob Fijnheer; Anja Ten Brinke; Alexander B Meijer; Floris P J van Alphen; Timo K van den Berg; Jonas J H Graversen; Soren K Moestrup; Jan Voorberg Journal: Blood Adv Date: 2017-01-16
Authors: Mohammad S Abdelgawwad; Wenjing Cao; Liang Zheng; Nicole K Kocher; Lance A Williams; X Long Zheng Journal: Arterioscler Thromb Vasc Biol Date: 2018-11 Impact factor: 8.311
Authors: Douglas B Cines; Keith R McCrae; X Long Zheng; Bruce S Sachais; Eline T Luning Prak; Don L Siegel Journal: Blood Date: 2012-09-10 Impact factor: 22.113